Best Options Strategy for KURA
Looking for the best options strategy for Kura Oncology, Inc. (KURA)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live KURA option chain right now, and a simple map from your view on KURA to the strategy that fits it. Model any of them in the calculator before you trade.
About KURA
Kura Oncology, Inc. (KURA) is a major company in Biotechnology. Options traders on KURA tend to watch , since these can drive large moves in the share price.
About Kura Oncology, Inc.
Kura Oncology is a biopharmaceutical company focused on developing cancer treatments. The company's flagship product, KOMZIFTI (ziftomenib), is an oral menin inhibitor that has reached commercialization. Beyond this approved medicine, Kura maintains a pipeline of experimental compounds in clinical development, including darlifarnib, which is being studied in combination with other targeted drugs across various solid tumor types, and KO-7246, a next-generation menin inhibitor being explored for both cancer applications and metabolic disorders like diabetes and cardiovascular disease. The company is based in San Diego, California.
Kura generates revenue primarily from sales of KOMZIFTI. The company's business model depends on successfully advancing its pipeline candidates through clinical trials and obtaining regulatory approval, which would enable additional revenue streams as those medicines reach the market. Success hinges on demonstrating that its experimental treatments work effectively in their respective indications and can compete in the oncology and metabolic disease markets.
Today's top-scoring strategy for KURA
Our engine ranks defined-risk strategies on the live KURA chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $7 | $0.10 |
| Sell | 1× | PUT | $11 | $1.98 |
| Sell | 1× | CALL | $11 | $0.42 |
| Buy | 1× | CALL | $15 | $0.20 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Live scan from 2026-07-02 · quotes delayed ~15 minutes
Implied volatility
KURA is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 99% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on KURA currently price in about 99% implied volatility, versus roughly 73% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.
Off that volatility, the options market is pricing a move of about ±$2.12 (±20%) in KURA by 2026-07-17 — a range of roughly $8.7 to $12.94. Strikes inside that band hold most of the premium and see most of the action.
Liquidity and tradeability
KURA options are thinly traded, with wide bid-ask spreads around 35.3% near the money that eat into any edge — favour simple single-leg or tight defined-risk trades, and always use limit orders.
Earnings & IV crush
KURA's next earnings report is due around August 6, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $985M
- Beta (vs market)
- 0.36
- 52-week range
- $5.45–$12.49 (76% up the range)
- Short interest
- 16.9% of float · 6.5 days to cover
With 16.9% of KURA's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
Other strong setups for KURA
If your view on KURA differs, these also scored well in the latest scan:
How to choose an options strategy for KURA
Start with your outlook on KURA, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while KURA stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open KURA in the free calculator →
Frequently asked questions
What is the best options strategy for KURA?
It depends on your outlook. Bullish traders often use a long call or bull call spread on KURA; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are KURA options liquid enough to trade?
Kura Oncology, Inc. (KURA) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade KURA options?
Buying a single KURA call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade KURA or any security. Do your own research.
What does Kura Oncology, Inc. do?
Kura Oncology, Inc. (KURA) operates in the Biotechnology industry. The "About Kura Oncology, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Kura Oncology, Inc. pay a dividend?
Kura Oncology, Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
When does Kura Oncology, Inc. next report earnings?
Kura Oncology, Inc.'s next earnings are expected around August 6, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to KURA
Comparing KURA with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 4930 Directors Place, Suite 500, San Diego, CA, 92121, United States
- Industry
- Biotechnology
- Employees
- 260
- CEO
- Dr. Troy Edward Wilson J.D., Ph.D.
- Phone
- 858 500 8800
- Website
- kuraoncology.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.